Cellular Transplantation of Autologous Bone Marrow-Derived Stem Cells Following Myocardial Infarction
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Safety as measured by holter monitor, laboratory assessments, and cardiac MRI
研究概览
简要总结
The goal of this study is to determine the safety of giving a patient's own bone marrow-derived stem cells delivered with a catheter (tube) into the coronary arteries (blood vessels of the heart). Stem cells are simple cells produced by the bone marrow that can develop into many types of cells. It is possible that these cells will decrease the size of damage caused to the heart from a heart attack and increase the pumping efficiency of the heart; which can be decreased due to a heart attack. The stem cells will be taken from bone marrow and then given back into the heart vessels.
详细描述
This protocol will test the hypothesis that an intracoronary infusion of autologous, unfractionated, bone marrow mononuclear cells will attenuate infarct size and improve left-ventricular function in 60 patients following an acute anterior myocardial infarction who have undergone successful revascularization with PTCA/stenting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients age at least 21 years of age
- •Patients with an acute anterior myocardial infarction limited to the proximal or mid-LAD with an artery diameter of at least 2.5 mm.
- •Ability to undergo cell therapy procedure within 2 to 7 days following acute MI and PTCA/stenting.
- •Ejection fraction following reperfusion with PTCA/stenting is between 30% and 50% as assessed by left-ventriculography or echocardiography.
- •Consent to protocol and agree to comply with all follow-up visits and studies.
排除标准
- •History of sustained ventricular arrhythmias not related to their acute myocardial infarction who do not have an ICD.
- •Require coronary artery bypass surgery or percutaneous revascularization due to the presence of residual coronary stenosis > 70% luminal obstruction in the non-infarct related vessel.
- •History of malignancy within the past 5 years excluding non-melanoma skin cancer or cervical cancer in-situ.
- •History of anemia (Hb < 9.0 mg/dl).
- •History of thrombocytosis.
- •PT or PTT greater than the upper limits of normal.
- •Life expectancy less than one year.
- •Patients on chronic dialysis.
- •History of untreated alcohol or drug abuse.
- •Currently enrolled in another Investigational drug or device trial.
- •History of stroke or TIA within the past 6 months.
- •History of severe valvular heart disease (aortic valve area < 1.0 cm2 or > 3+ mitral regurgitation.
- •Pregnancy
- •Subjects who are HIV, hepatitis B or C positive.
- •Patients with active inflammatory or autoimmune disease on chronic immunosuppressive therapy.
- •Contraindications to cardiac MRI
研究组 & 干预措施
Cell therapy
Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
干预措施: Autologous, Unfractionated Bone Marrow Mononuclear Cells (Drug)
结局指标
主要结局
Safety as measured by holter monitor, laboratory assessments, and cardiac MRI
时间窗: 6 months
次要结局
- Improvement of left ventricular function as assessed by serial measurements of infarct size and LV function by cardiac MRI in the active treatment group versus placebo.(6 months)